

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTY. DOCKET NO. 068911-0126	SERIAL NO 10/557,293
		APPLICANT John G. Babisch	
(PTO-1449)		FILING DATE 12/20/2006	GROUP 1655

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code(s if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 3,451,821	6/24/69	Todd et al.	
	2	US 4,389,421	6/21/1983	Palamand	
	3	US 5,041,300	8/20/1991	Todd et al.	
	4	US 5,919,813	7/6/99	De Juan	
	5	US 6,291,483	9/18/01	Upadhyay et al.	
	6	US 6,482,456	11/19/2002	Yokoo, et al.	
	7	US 6,482,456	11/19/02	Yokoo, et al.	
	8	US 6,689,388	2/10/04	Kuhrt	
	9	US 6,790,459	9/14/04	Cheng et al.	
	10	US 7,195,785	3/27/07	Babisch et al.	
	11	US 7,205,151	4/17/07	Babisch et al.	
	12	US 7,270,835	9/18/07	Tripp et al.	
	13	US 7,279,185	10/9/07	Babisch et al.	
	14	US 7,332,185	2/19/08	Babisch et al.	
	15	US 7,431,948	10/7/08	Tripp et al.	
	16	US 20020028852	3/7/02	Ghai, et al.	
	17	US 20020156087	10/24/02	Nuss et al.	
	18	US 20030003212	1/1/03	Chien et al.	
	19	US 20030180402	9/25/03	Jia et al.	
	20	US 20030228369	12/1/03	Kuhrt	
	21	US 20040115290	6/17/04	Tripp et al.	
	22	US 20040151792	8/5/04	Tripp et al.	
	23	US 20050042317	2/24/05	Babisch et al.	
	24	US 20050129791	6/16/05	Babisch et al.	
	25	US 20050192356	9/1/05	Babisch et al.	
	26	US 20060127511	6/15/06	Tripp et al.	
	27	US 20060127512	6/15/06	Tripp et al.	
	28	US 20060127513	6/15/06	Tripp et al.	
	29	US 20060127514	6/15/06	Tripp et al.	
	30	US 20060127515	6/15/06	Tripp et al.	
	31	US 20060127516	6/15/06	Tripp et al.	
	32	US 20060127517	6/15/06	Tripp et al.	
	33	US 20060193933	8/31/06	Tripp et al.	
	34	US 20070020352	1/25/07	Tripp et al.	
EXAMINER			DATE CONSIDERED		
/Michael Meller/ (07/29/2010)					

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO.
068911-0126

SERIAL NO
101557.293

SHEET 3 OF 5

(PTO-1449)

U.S. PATENT DOCUMENTS

APPLICANT
John G. Babisch
FILING DATE
10/15/2022

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M-N-TRP-509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION**

(PTO-1449)

ATTY. DOCKET NO. **06891-0126**

SERIAL NO
10/557,293

APPLICANT
John G. Babish

FILING DATE **12/20/2006** GROUP **1655**

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes (if known) Category Number & Kind	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Reappear Figures		Translation Yes No
					Plaintext	Abstract	
1	DE 3 931 147		3/28/91	Solong Natural Ltd			
2	DE 199393350		2/22/01	Co KG			
3	EP 0606599 A1		7/20/94	Müller Brekking Co.			
4	EP 0681029 A2		11/8/95	Zuckerfabrik Schütt			
5	GB 2 330076		4/14/90	S. S. Steiner, Inc.			
6	JP 10152428		6/3/98	Kanebo Ltd			
7	JP 2002-12550		1/15/02	Novit Co. LTD			
8	JP 3 6311219		9/2/88	TAIYO KORYO KK			
9	JP 4 09067245		3/11/97	Asahi Breweries, Ltd.			
10	JP 4 2021378		7/22/92	Asahi Breweries, Ltd.	Abstract		
11	SU 1247011		7/30/86	Aerozel Trust	Abstract		
12	WO 03/082249		10/9/03	Alcon, Inc.	Abstract		
13	WO 99/61038		12/1/1999	Adams Food Ltd.			
14	ZA 200000857		8/29/01	Mark, Anna-Susanna			
15	CN 1 203268		12/30/98	Hu			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

- 1 "Information on amphotericin Product", downloaded from Internet 8/30/02.
- 2 Albal, M.V., et al., "Clinical evaluation of berberine in mycotic infections," Indian J. Ophthalmol 31:91-2 (1986)
- 3 Bernabeo, et al, Rev. Esp. Enferm. Dig. 95: 621-624 and 625-628 (2003)
- 4 Byrne, et al, J. Chem. Soc. (C) 2810 (1971)
- 5 Carroccio, et al, Clin. Chem. 49:861-867 (2003)
- 6 Carson, J. Am. Chem. Soc. 73:1850-1851 (1951)
- 7 Chou, et al, Adv. enzyme regul 22:27-55 (1984)
- 8 Cohen, Protein Kinases - the major drug targets of the twenty-first century? Nature Reviews, 1: 309-315 (2002)

EXAMINER

07/29/2007

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered.
1. Include copy of this form with next communication to applicant.
4. Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

/Michael

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

ATTY. DOCKET NO.
06891-0126

SERIAL NO
10/557,293

SHEET 4 OF 5

(PTO-1449)

OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
10	Davies, WL. Abstract - Fertiliser, Feeding stuffs and Farm Supplies J. 11:1694 (1926)	
11	Exercise as Treatment for Arthritis, Rheumatic and Immunologic Diseases. Cleveland Clinic. www.clevelandclinic.org . March 14, 2000. 3 Pages.	
12	Gerhauser, "Beer Constituents as Potential Cancer Chemos preventive Agents. EP Journal of Cancer 4:1, 1941-1954; (2005)	
13	Gianini, "Studies on Antihypertensive and Antispasmodic Activities of Methanol Extract of Acacia nilotica Pods." Phytotherapy Research 13: 665-669 (1999)	
14	Goldstein, et al. Ann. J. Gastroenterol. 96:1019-1027 (2001)	
15	Hamborg, et al. J. Bio. Chem. 246:6713-6721 (1971)	
16	International Search Report for PCT/US06/30920, 08/03/07, 3 Pages	
17	International Search Report for PCT/US06/47196	
18	Jach, Poggl. Dermatol. 65(4):379-382 (1978)	
19	Kaltner, D., Technische Universität München. (11/3/2000), pp. 1-193. Plus Tabs AH1-AH31.	
20	Kaltner, Investigation of formation of Hops Aroma and technological Measures for Products of Hops-Aromatic Beers. Technical University of Munich. 7 pp	
21	Kanematsu, et al. J. Bone Miner Res 12(1):1789-1796 (1997)	
22	Lopes, Curr. Med Res Opin. 8:145-149 (1982)	
23	Newmark, et al. "Beyond Aspirin: nature's answer to arthritis, cancer & Alzheimer's disease." John Press (2000) release 7; pp. 147-151, 248	
24	Parret, et al. Inflamm. Res 47, Supplement 2s93-s101 (1998)	
25	Pipka, et al. Stand. J. Gastroenterol. Suppl. 16:7,32-35 (1989)	
26	Poulios, et al. J. Gastroenterol. Hepatol. 18:756-762 (2003)	
27	Provital Group. Rosmarinic-acid Botany, 2007, 9 pages	
28	Q&A, 3 pages (2004)	
29	Rahman, M.M., et al., "Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling." J. Lipid Res. 47(8): 1739-1748, (2006)	
30	Smith, et al., Natural Foam Stabilizing and Bittering Compounds Derived From Hops. Journal of the American Society of Brewing Chemists, Vol. 56, No. 2, 1998, pp. 52-57	
31	Stevens, Kanthorinol and related Prenylflavonoids from Hops and Beer. To Your Good Health, Science Direct, 21pp (2004)	
32	Suh, et al. Cancer Res. 58:717-723 (1998)	
33	Supplementary Partial European Search Report for related European Patent Application No. 05723895.8 5 Pages. (2007)	
34	Tanigashira, et al. Biosci. Biotech. Biochem. 59(4):740-742 (1995)	
35	The national, 3 pages (1999)	
EXAMINER	Miller (07/20/2008)	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

/Michael

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

/Micha

**INFORMATION DISCLOSURE STATEMENT BY
APPLICANT**
(Use as many sheets as necessary)

		Complete if known	
Application Number		10/557,293	
Filing Date		December 20, 2006	
First Named Inventor		John G. Babisch	
Art Unit		1655	
Examiner Name		Michael V. Meller	
Docket Number		068911-0126	

CERTIFICATION STATEMENT

Please See 37 CFR 1.97 and 1.98 to make the appropriate selection(s)

Items contained in this Information Disclosure Statement were first cited in any communication from a foreign patent office in a counterpart foreign application;

In accordance with the provisions of 37 CFR 1.55, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

OR

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.55(c) more than three months prior to the filing of this Information Disclosure Statement.

This Statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.

The Commissioner is hereby authorized to charge the fee pursuant to 37 CFR 1.17(P) in the amount of \$180.00, or further fees which may be due, to Deposit Account 50-1133.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.


Attabak R. Royee, Reg. No. 58,637

McDermond Vill & Emery LLP

28 State Street
Boston, MA 02108
Tel. (617) 535-4082
Fax (617) 535-3800

Date: July 29, 2010

/Michael Meller/ (07/29/2010)